Merck Vs. AbbVie: Which Is Better Buy As The Patent Cliffs Approach?

Nov. 22, 2022 11:00 AM ETAbbVie Inc. (ABBV), MRKAZN, AZNCF, BAYRY, BAYZF, BLUE, BMYMP, PFE, RHHBF, RHHBY, RHHVF, SGEN28 Comments
Vera Glebova profile picture
Vera Glebova
693 Followers

Summary

  • In this article, I will be comparing AbbVie and Merck to see which is better positioned for its patent cliff.
  • With the acquisition of Seagen, Merck will have a fairly broad oncology portfolio. However, this will not fully offset the aftermath of Keytruda's LOE.
  • AbbVie has a pretty decent future after Humira's LOE, given strategic acquisitions of Pharmacyclics and Allergan and Rinvoq/Skyrizi rise.
  • I like AbbVie more than Merck.

Разноцветные таблетки, разбросанные из белого пластикового контейнера для лекарств

igoriss/iStock via Getty Images

Thesis

AbbVie (NYSE:ABBV) and Merck (NYSE:MRK) are the 3rd and the 5th largest pharma companies in the world. Both companies have brought investors a decent profit in a falling market. Looking further, the future may look

Seagen drug portfolio

Seagen

Merck revenue with Seagen

Edmund Ingham

Rinvoq and Skyrizi sales projection

Abbvie

This article was written by

Vera Glebova profile picture
693 Followers
Individual investor with two-year experience. Current student, studying economics and finance. Exploring opportunities to invest in this tough market.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (28)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.